Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Head & Neck 2Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Sarcoma 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × AH 111585 × Dermatologic × Clear all
NCT00565721 2014-08-18

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

GE Healthcare

Phase 2 Completed
33 enrolled 23 charts
CNSDermatologicHead & NeckSarcomaThoracic

Glioma, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡